{"disease":{"id":"prophylaxis-of-primary-or-recurrent-stage-ta-and-or-t1-papillary-tumors-following-transurethral-resection-tur","name":"prophylaxis of primary or recurrent stage ta and or t1 papillary tumors following transurethral resection tur"},"drugs":{"marketed":[{"drug_id":"bacillus-calmette-guerin","indication_name":"Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"bcg","guideline_body":"FDA label","recommendation":"TICE BCG is indicated for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).","line_of_therapy":"adjuvant","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}